[8-K] Sensei Biotherapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

What happened: Sensei Biotherapeutics issued a press release announcing its financial results for the quarter ended June 30, 2025.

Why it matters: The press release is attached to this Form 8-K as Exhibit 99.1, so investors can read the company’s reported results and commentary. The filing explicitly states the exhibit is being furnished, not filed, and therefore is not treated the same as a formally filed disclosure or incorporated by reference.

What to do: Review Exhibit 99.1 for the actual figures and management comments, since this 8-K itself does not include the financial numbers.

Insights

Securities Analyst

TL;DR: Routine earnings press release furnished; 8-K contains no financial detail.

The company used an 8-K to furnish a press release announcing results for the quarter ended June 30, 2025. The form clarifies the press release is an exhibit and is "furnished, not filed," which limits legal exposure under the Exchange Act. Because this filing does not include the underlying numbers, it does not by itself change valuation assumptions; investors must read Exhibit 99.1 to assess revenue, profit, cash flow, or guidance impacts.

Corporate Governance Expert

TL;DR: Governance disclosure is procedural and standard; no new governance matters disclosed.

The 8-K follows standard disclosure practice by attaching a press release as Exhibit 99.1 and stating it is furnished, not filed. There is no indication of executive changes, related-party transactions, or amendments to governance documents in this filing. From a governance standpoint, the filing is informational and routine; any material implications depend on the content of the attached press release.

false 0001829802 0001829802 2025-08-05 2025-08-05

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 5, 2025

Sensei Biotherapeutics, Inc.

(Exact Name of Registrant as Specified in its Charter)

Delaware		001-39980		83-1863385
(State or Other Jurisdiction of Incorporation)		(Commission File Number)		(IRS Employer Identification No.)
1405 Research Blvd, Suite 125 Rockville, MD				20850
(Address of Principal Executive Offices)				(Zip Code)

Registrant’s telephone number, including area code: (240) 243-8000

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class		Trading symbol		Name of each exchange on which registered
Common Stock		SNSE		The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 5, 2025, Sensei Biotherapeutics, Inc. issued a press release announcing its financial results for the quarter ended June 30, 2025. A copy of the press release is attached hereto as Exhibit 99.1.

The information in this Item 2.02 and the exhibit attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, whether filed before or after the date hereof and regardless of any general incorporation language in such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit Number		Exhibit Description
99.1		Press Release of Sensei Biotherapeutics, Inc., dated August 5, 2025
104		The cover page from this Current Report on Form 8-K, formatted in Inline XBRL

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

						Sensei Biotherapeutics, Inc.
Date: August 5, 2025						/s/ Christopher W. Gerry
						Christopher W. Gerry
						General Counsel and Secretary

3

FAQ

What did Sensei Biotherapeutics (SNSE) report in this 8-K?

Sensei Biotherapeutics furnished a press release announcing financial results for the quarter ended June 30, 2025; the release is attached as Exhibit 99.1.

Is the press release in the 8-K "filed" with the SEC?

No. The filing states the press release is furnished, not filed, and therefore is not deemed filed for purposes of the Exchange Act.

Where can I find the actual financial numbers?

The actual figures and management commentary are in the press release attached as Exhibit 99.1 to this Form 8-K; the 8-K text itself does not include the numbers.

What period do the results cover?

The press release announces results for the quarter ended June 30, 2025.

What is Sensei Biotherapeutics' ticker and exchange?

The company’s common stock trades as SNSE on The Nasdaq Stock Market LLC.